Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
about
A new recombinant factor VIII: from genetics to clinical use.A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs.Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogsAllometric scaling and prediction of concentration-time profiles of coagulation factors in humans from animals.Advances in the treatment of inherited coagulation disorders.Blood Clotting Factor VIII: From Evolution to Therapy.Novel products for haemostasis - current status.Innovative approach for improved rFVIII concentrate.Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.Turoctocog alfa for the treatment of hemophilia a.The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia AUpdates from guardian™: a comprehensive registration programme.PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.Emerging drugs for the treatment of hemophilia A and B.Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)).Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
P2860
Q30370282-FE3AD500-9CE0-4BB6-8BA0-ACAF0AA5AF5EQ30426130-4C55B432-747D-4573-B632-09B9DA578E06Q36912731-0B3615ED-9B67-4CD6-9786-7AAC5CD94999Q37585275-F0FD6022-C566-4E2D-96E4-097A3D120FA9Q37591484-9459B107-BBC5-4296-9B33-64C9E7789012Q38079864-22A2DD66-92F3-4FE5-98B2-1A4B6B0E9EF5Q38100271-5FF9A6F1-ECD7-4861-BD63-ECA1C3C3A105Q38118763-AA22C065-9822-4940-AF8A-CD9F2A3714DBQ38206849-44579F3F-2B7B-4015-9486-8E4BE0FBF772Q38207134-4A36601C-D4D4-425D-ACB7-A741103A4966Q38209486-CD9A8886-91A9-46AF-93A2-A807E6615ECDQ38232780-D41BC046-57FD-47C0-B64D-31A7971E2F82Q38286285-27E089AD-0C09-4E74-BDEE-013B5D823A0BQ38408739-4E8E7667-30DC-4068-8BFF-C7FA030E3E92Q38672491-E4A877C4-5D0C-404B-B78B-695681A1AC69Q38705742-EFE9F4AC-A280-471F-B079-68657BC2BBCCQ38933707-3BDADEB6-A6FF-44BB-A2FE-E309ACAEA38DQ39074627-D9705714-5B53-416C-B108-741BCC220241Q39475869-B60BE8F0-8AF2-4459-83F6-ED0380B19715Q40573329-C4EEFF2D-5FC8-4CE3-B2F0-7826134B20DDQ45856520-50EA8877-5AAD-41AC-A32B-691FEF5D711AQ45878529-FBA3F3CC-7DB3-461D-A4BD-3EE12204AF6DQ45884927-99023332-1E38-476A-A193-E4D68AA3CCC6Q45887360-5DD98D4C-733F-4523-AABA-D55584AD6822Q45887401-00C3FE8A-6C67-48A5-B470-67982C046853
P2860
Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Bioequivalence between two ser ...... nts with severe haemophilia A.
@en
Bioequivalence between two ser ...... nts with severe haemophilia A.
@nl
type
label
Bioequivalence between two ser ...... nts with severe haemophilia A.
@en
Bioequivalence between two ser ...... nts with severe haemophilia A.
@nl
prefLabel
Bioequivalence between two ser ...... nts with severe haemophilia A.
@en
Bioequivalence between two ser ...... nts with severe haemophilia A.
@nl
P2093
P2860
P921
P1433
P1476
Bioequivalence between two ser ...... ents with severe haemophilia A
@en
P2093
E Santagostino
R Klamroth
U Martinowitz
P2860
P304
P356
10.1111/J.1365-2516.2011.02495.X
P50
P577
2011-03-28T00:00:00Z